New developments in cancer treatment require medication experts-here's how you can become that expert.
Lisa M. Holle, PharmD, BCOP, FHOPA
Advertisement
Lisa M. Holle, PharmD, BCOP, FHOPA is an assistant clinical professor, University of Connecticut School of Pharmacy, Storrs, Conn.
Articles by Lisa M. Holle, PharmD, BCOP, FHOPA
Here: an overview of atezolizumab, the first new drug in two decades for bladder cancer and now approved for NSCLC.
FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
Advertisement
Latest Updated Articles
- Atezolizumab for Urothelial Carcinoma and Non-Small Cell Lung Cancer
Published: February 8th 2017 | Updated:
- FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting
Published: June 10th 2016 | Updated:
- Ixazomib for multiple myeloma
Published: November 11th 2016 | Updated:
- FDA approves lixisenatide for type 2 diabetes
Published: December 19th 2016 | Updated:
Why You Should Become Board Certified in OncologyPublished: June 11th 2018 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Severe COVID-19 Increases Stroke Risk for Patients With Asthma
2
How Community Pharmacists Are Proactively Managing Patients’ Migraines | NCPA 2025
3
The Variety of Migraine Treatment Options Opens the Door for Pharmacy Services | NCPA 2025
4
Pharmacists Help Patients Stay Adherent to COPD Therapy, Improving Overall Quality of Life
5
